Details werden geladen...
Press Release: Novartis Fabhalta(R) (iptacopan) -2- | 17.07.26 | finanzen.at
6. Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012;7(6):e38904. ...
Ähnliche Seiten
Press Release: Novartis Fabhalta(R) (iptacopan) -2- | 17.07.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/press-release-novartis-fabhaltar-iptacopan-2--1036334570
Press Release: Novartis data at EULAR 2026 -2- | 01.06.26 | finanzen.at
https://www.finanzen.at/nachrichten/aktien/press-release-novartis-data-at-eular-2026-2--1036211777Press Release: Novartis to highlight Rhapsido(R) -2- | 08.06.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/press-release-novartis-to-highlight-rhapsidor-2--1036230932Press Release: Novartis data at EULAR 2026 -2- | 01.06.26 | finanzen.ch
https://www.finanzen.ch/nachrichten/aktien/press-release-novartis-data-at-eular-2026-2--1036211774Press Release: Novartis Fabhalta(R) (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney functio... | 17.07.26 | finanzen.at
https://www.finanzen.at/nachrichten/aktien/press-release-novartis-fabhaltar-iptacopan-receives-fda-traditional-approval-as-first-and-only-complement-inhibitor-to-significantly-slow-kidney-functio--1036334571